Source comparison
Comparison Table: Peptides for Sexual Performance Anxiety
PT-141 (Bremelanotide) MC4R agonist. Increases dopamine, reduces GABAergic inhibition of arousal Phase III trials in HSDD; statistically significant improvement in desire and arousal scores 1.75mg subcutaneous 45 min before activity 30–60 minutes Most direct m
This comparison does not assign a generated winner or score.
- PT-141 (Bremelanotide)
- MC4R agonist. Increases dopamine, reduces GABAergic inhibition of arousal
- Phase III trials in HSDD; statistically significant improvement in desire and arousal scores
- 1.75mg subcutaneous 45 min before activity
- 30–60 minutes
- Most direct mechanism for centrally mediated performance anxiety. Addresses dopamine suppression at the hypothalamic level
- Oxytocin (intranasal)
- Amygdala modulation. Reduces threat perception, enhances parasympathetic tone
- fMRI studies show reduced amygdala activation to fear stimuli; observational studies in sexual arousal contexts
- 24–40 IU intranasal 15–30 min before activity
- 15–30 minutes
- Effective for anxiety-driven arousal suppression; particularly relevant when fear of judgment or rejection is the primary trigger
- Selank
- GABAergic anxiolytic. Lowers cortisol, reduces generalised anxiety without sedation
- Russian clinical trials in generalised anxiety disorder; significant anxiety reduction without cognitive impairment
- 300–600mcg intranasal or subcutaneous daily for sustained effect
- 30–90 minutes (acute); 7–14 days (sustained baseline reduction)
- Best used as a daily baseline anxiolytic rather than acute pre-activity dosing. Reduces the chronic stress load that predisposes to performance anxiety
- Citrulline / Arginine
- Nitric oxide precursor. Vasodilation, improved penile blood flow
- Randomised controlled trials in vascular ED; minimal evidence in performance anxiety
- 3–6g oral daily
- 60–90 minutes
- Addresses vascular insufficiency, not central anxiety. Ineffective for psychogenic performance issues
- Melanotan II
- Non-selective melanocortin agonist (MC1R, MC3R, MC4R, MC5R)
- Phase II trials discontinued due to adverse event profile
- Not recommended for clinical use
- 30–120 minutes
- Off-target effects (nausea, pigmentation, uncontrolled erections) outweigh benefits. PT-141 is the refined, selective alternative